nach oben

Erschienen in:

01.09.2009 | Original Article

Negative Impact of Blood Transfusion on Recurrence and Prognosis of Hepatocellular Carcinoma After Hepatic Resection

verfasst von: Hiroaki Shiba, Yuichi Ishida, Shigeki Wakiyama, Tomonori Iida, Michinori Matsumoto, Taro Sakamoto, Ryusuke Ito, Takeshi Gocho, Kenei Furukawa, Yuki Fujiwara, Shoichi Hirohara, Takeyuki Misawa, Katsuhiko Yanaga

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

In perioperative management of hepatic resection for hepatocellular carcinoma, excessive blood loss and blood transfusion greatly influence postoperative complications and prognosis of the patients. We evaluated the influence of blood products use on postoperative recurrence and prognosis of patients with hepatocellular carcinoma.

Methods

The subjects were 66 patients who underwent elective hepatic resection for hepatocellular carcinoma without concomitant microwave or radiofrequency ablation therapy nor other malignancies between January 2001 and June 2006. We retrospectively investigated the influence of the use of blood products including red cell concentration and fresh frozen plasma on recurrence of hepatocellular carcinoma and overall survival.

Results

In multivariate analysis, the dose of blood products transfusion was a significant predictor of disease-free and overall survival. Both disease-free and overall survival rates of those who were given blood products were significantly worse than those who did not receive. On the other hand, in univariate analysis of disease-free and overall survival after hepatic resection and clinical variables, the amount of blood loss was not a significant predictor of recurrence or death.

Conclusion

Transfusion of blood products is associated with increased recurrence rate and worse survival after elective hepatic resection for patients with hepatocellular carcinoma.

Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993;113:612–618.PubMed

Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, Oriyama T, Furukawa K, Kawamura E. Prognostic factors after hepatectomy for hepatocellular carcinomas. Cancer 1990;65:1104–1110.PubMedCrossRef

Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70.PubMedCrossRef

Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg 1995;19:35–41.PubMedCrossRef

Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790–800.PubMedCrossRef

Chen MF, Hwang TL, Jeng LB, Jan YY, Wang CS, Chou FF. Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg 1989;124:1025–1028.PubMed

Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N, Morioka Y. Postoperative recurrence of hepatocellilar carcinoma. Ann Surg 1990;211:28–33.PubMedCrossRef

Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993;105:488–494.PubMed

Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114–117.PubMedCrossRef

10.

Yanaga K, Okudaira S, Kanematsu T, Marsh JW. Hepatic Resection for Hepatocellular Carcinoma. In Carr B, ed. Hepatocellular Cancer: Diagnosis and Treatment. Totowa: Humana Press, 2005, pp 185–198.CrossRef

11.

Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion 1990;30:651–658.PubMedCrossRef

12.

Blajchman MA, Bordin JO. Mechanisms of transfusion-associated immunosuppression. Curr Opin Hematol 1994;1:457–461.PubMed

13.

Blajchman MA. Immunomodulation and blood transfusion. Am J Ther 2002;9:389–395.PubMedCrossRef

14.

Magee CC, Sayegh MH. Peptide-mediated immunosuppression. Curr Opin Immunol 1997;9:669–675.PubMedCrossRef

15.

Krensky AM, Clayberger C. Structure of HLA molecules and immunosuppressive effects of HLA derived peptides. Int Rev Immunol 1996;13:173–185.PubMedCrossRef

16.

Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Mizuno S, Makuuchi M. Perioperative blood transfusion promotes recurrence of hepatocellular carcinoma after hepatectomy. Surgery 1994;115:303–309.PubMed

17.

Yanaga K, Kanematsu T, Takenaka K, Matsumata T, Yoshida Y, Sugimachi K. Hepatic resection for hepatocellular carcinoma in elderly patients. Am J Surg 1988;155:238–241.PubMedCrossRef

18.

Nagao T, Inoue S, Goto S, Mizuta T, Omori Y, Kawano N, Morioka Y. Hepatic resection for hepatocellular carcinoma: clinical features and long-term prognosis. Ann Surg 1987;205:22–40.CrossRef

19.

Asahara T, Katayama K, Itamoto T, Yano M, Hino H, Okamoto Y, Nakahara H, Dohi K, Moriwaki K, Yuge O. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999;23:676–680.PubMedCrossRef

20.

Tralhao JG, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology 2007;54:1200–1206.PubMed

21.

Sugita S, Sasaki A, Iwaki K, Uchida H, Kai S, Shibata K, Ohta M, Kitano S. Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intra-operative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol 2008;34:339–345.PubMed

22.

Foster RS, Costanza MC, Foster JC, Wanner MC, Foster CB. Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer 1985;55:1195–1201.PubMedCrossRef

23.

Younes RN, Rogatko A, Brennan MF. The influence of intra-operative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg 1991;214:107–113.PubMedCrossRef

24.

Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann Surg 1992;216:633–638.PubMedCrossRef

25.

Parrott NR, Lennard TW, Taylor RM, Proud G, Shenton BK, Johnston ID. Effect of perioperative blood transfusion on recurrence of colorectal cancer. Br J Surg 1986;73:970–973.PubMedCrossRef

26.

Blumberg N, Agarwal MM, Chuang C. Relation between recurrence of cancer of the colon and blood transfusion. Br Med J 1985;290:1037–1039.CrossRef

27.

Stephenson KR, Steinberg SM, Hughes KS, Vetto JT, Sugarbaker PH, Chang AE. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988;208:679–687.PubMedCrossRef

28.

Little AG, Wu HS, Ferguson MK, Ho CH, Bowers VD, Segalin A, Staszek VM. Perioperative blood transfusion adversely affects prognosis of patients with stage I non-small-cell lung cancer. Am J Surg 1990;160:630–632.PubMedCrossRef

29.

Tartter PI, Burrows L, Kirschner P. Perioperative blood transfusion adversely affects prognosis after resection of Stage I (subset N0) non-oat cell lung cancer. J Thorac Cardiovasc Surg 1984;88:659–662.PubMed

30.

Hyman NH, Foster RS, DeMeules JE, Costanza MC. Blood transfusions and survival after lung cancer resection. Am J Surg 1985;149:502–507.PubMedCrossRef

31.

Moores DW, Piantadosi S, McKneally MF. Effect of perioperative blood transfusion on outcome in patients with surgically resected lung cancer. Ann Thorac Surg 1989;47:346–351.PubMedCrossRef

32.

Crowe JP, Gordon NH, Fry DE, Shuck JM, Hubay CA. Breast cancer survival and perioperative blood transfusion. Surgery 1989;106:836–841.PubMed

33.

Nowak MM, Ponsky JL. Blood transfusion and disease-free survival in carcinoma of the breast. J Surg Oncol. 1984;27:124–130.PubMedCrossRef

34.

Kaneda M, Horimi T, Ninomiya M, Nagae M, Mukai K, Takeda I, Shimoyama H, Chohno S, Okabayashi T, Kagawa S. Adverse affect of blood transfusions on survival of patients with gastric cancer. Transfusion 1987;27:375–377.PubMedCrossRef

35.

Fong Y, Karpeh M, Mayer K, Brennan MF. Association of perioperative transfusions with poor outcome in resection of gastric adenocarcinoma. Am J Surg 1994;167:256–260.PubMedCrossRef

36.

Shiba H, Ishii Y, Ishida Y, Wakiyama S, Sakamoto T, Ito R, Gocho T, Uwagawa T, Hirohara S, Kita Y, Misawa T, Yanaga K. Assessment of blood products use as predictors of pulmonary complications and surgical site infection after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2009;16:69–74.PubMedCrossRef

37.

Vamvakas EC, Carven JH. Exposure to allogeneic plasma and risk of postoperative pneumonia and/or infection in coronary artery bypass graft surgery. Transfusion 2002;42:107–113.PubMedCrossRef

38.

Matsumata T, Ikeda Y, Hayashi H, Kamakura T, Taketomi A, Sugimachi K. The association between transfusion and cancer-free survival after curative resection for hepatocellular carcinoma. Cancer 1993;72:1866–1871.PubMedCrossRef

39.

Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival. Cancer 2001;91:771–778.PubMedCrossRef

40.

Yamamoto J, Kosuge T, Saiura A, Sakamoto Y, Shimada K, Sano T, Takayama T, Sugawara Y, Yamaguchi T, Kokudo N, Makuuchi M. Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol 2007;37:287–295.PubMedCrossRef

41.

Zhou L, Rui JA, Wang SB, Chen SG, Qu Q, Chi TY, Wei X, Han K, Zhang N, Zhao HT. Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy. World J Surg 2007;31:1782–1787.PubMedCrossRef

42.

Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. Am J Surg 1995;169:589–594.PubMedCrossRef

43.

Bureau of Medicinal Safety, Ministry of Health and Welfare. Guidelines for administering blood preparations. Medical and Pharmaceutical Notification No. 715, June 10, 1999

44.

Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002;24:395–403.PubMedCrossRef

45.

Weiden PL, Bean MA, Schultz P. Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence. Cancer 1987;60:870–874.PubMedCrossRef

46.

Keller SM, Groshen S, Martini N, Kaiser LR. Blood transfusion and lung cancer recurrence. Cancer 1988;62:606–610.PubMedCrossRef

47.

Foster RS, Foster JC, Costanza MC. Blood transfusions and survival after surgery for breast cancer. Arch Surg 1984;119:1138–1140.PubMed

48.

Voogt PJ, van de Velde CJ, Brand A, Hermans J, Stijnen T, Bloem R, Leer JW, Zwaveling A, van Rood JJ. Perioperative blood transfusion and cancer prognosis: different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 1987;59:836–843.PubMedCrossRef

49.

Eickhoff JH, Andersen J, Laybourn C. Perioperative blood transfusion does not promote recurrence and death after mastectomy for breast cancer. The Danish Breast Cancer Cooperative Group. Br J Surg 1991;78:1358–1361.PubMedCrossRef

50.

van de Watering LM, Brand A, Houbiers JG, Klein Kranenbarg WM, Hermans J, van de Velde C. Cancer Recurrence and Blood Transfusion Study Group. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001;88:267–272.PubMedCrossRef

51.

Fan ST, Ng IO, Poon RT, Lo CM, Liu CL, Wong J. Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival. Arch Surg 1999;134:1124–1130.PubMedCrossRef

52.

de Boer MT, Molenaar IQ, Porte RJ. Impact of blood loss on outcome after liver resection. Dig Surg 2007;24:259–264.PubMedCrossRef

53.

Fujimoto J, Okamoto E, Yamanaka N, Tanaka T, Tanaka W. Adverse effect of perioperative blood transfusions on survival after hepatic resection for hepatocellular carcinoma. Hepatogastroenterology 1997;44:1390–1396.PubMed

54.

Hsu HC, Wu TT, Wu MZ, Wu CY, Chiou TJ, Sheu JC, Lee CS, Chen DS. Evolution of expression of hepatitis B surface and core antigens (HBsAg, HBcAg) in resected primary and recurrent hepatocellular carcinoma in HBsAg carriers in Taiwan: correlation with local host immune response. Cancer 1988;62:915–921.PubMedCrossRef

55.

Yamasaki H, Okamoto E, Komatsu T, Manabe Y, Shinka S. Relationship between general or specific immunoreactivity and prognosis in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother 1990;31:107–114.PubMedCrossRef

56.

Ayers RC, Robertson DA, Dewbury KC, Millward-Sadler GH, Smith CL. Spontaneous regression of hepatocellular carcinoma. Gut 1990;31:722–724.CrossRef

57.

Suzuki M, Okazaki N, Yoshino M, Yoshida T. Spontaneous regression of a hepatocellular carcinoma: a case report. Hepatogastroenterology 1989;36:160–163.PubMed

58.

Sato Y, Fujiwara K, Nakagawa S, Kanishima S, Ohta Y, Oka Y, Hayashi S, Oka H. A case of spontaneous regression of hepatocellular carcinoma with bone metastasis. Cancer 1985;56:667–671.PubMedCrossRef

59.

Ohta H, Sakamoto Y, Ojima H, Yamada Y, Hibi T, Takahashi Y, Sano T, Shimada K, Kosuge T. Spontaneous regression of hepatocellular carcinoma with complete necrosis: case report. Abdom Imaging 2005;30:734–737.PubMedCrossRef

60.

Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305–1308.PubMedCrossRef

61.

Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699–703.PubMedCrossRef

62.

Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immnomodulatory effects of allogeneic blood transfusions. Blood 1999;93:1770–1777.PubMed

63.

Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferrone S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 2000;12:195–203.PubMedCrossRef

64.

Puppo F, Ghio M, Contini P, Mazzei C, Indiveri F. Fas, Fas ligand, and transfusion immunomodulation. Transfusion 2001;41:416–418.PubMedCrossRef

65.

Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeated hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003;238:703–710.PubMedCrossRef

66.

Torzilli G, Makuuchi M, Inoue K, Takayama T, Sakamoto Y, Sugawara Y, Kubota K, Zucchi A. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg. 1999;134:984–992.PubMedCrossRef

67.

Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322–330.PubMedCrossRef

Titel: Negative Impact of Blood Transfusion on Recurrence and Prognosis of Hepatocellular Carcinoma After Hepatic Resection
verfasst von: Hiroaki Shiba
Yuichi Ishida
Shigeki Wakiyama
Tomonori Iida
Michinori Matsumoto
Taro Sakamoto
Ryusuke Ito
Takeshi Gocho
Kenei Furukawa
Yuki Fujiwara
Shoichi Hirohara
Takeyuki Misawa
Katsuhiko Yanaga
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 9/2009
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-009-0963-y

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Negative Impact of Blood Transfusion on Recurrence and Prognosis of Hepatocellular Carcinoma After Hepatic Resection